No Data
Innovative Drugs and policies drive each other forward! Hong Kong stock pharmaceuticals strengthen against the trend, with Galactose Pharma rising over 25%.
① How will the recently introduced open policy in the Biomedical sector by the State Council affect the competitive landscape of the domestic Industry Chain? ② Can the CXO Industry expect a rebound from its lowest point?
Nomura Adjusts Innovent Biologics' Price Target to HK$54.60 From HK$58.09, Keeps at Buy
[Brokerage Focus] China International: In January, Global and China Medical financing showed signs of recovery, focusing on recommending companies with good annual report expectations.
Jinwu Finance | According to the renowned Medical database Artery Network Statistics, the total disclosed financing amount for the Global Medical Health Industry in January 2025 was 8.004 billion USD, an increase of 100.5% month-on-month from December. The disclosed financing amount for China's Medical Health Industry in January was 0.956 billion USD, increasing by 90.8% and 71.3% compared to November and December, respectively. After a significant decline in the total financing amount for the Global Medical Health Industry in 2022-23, there was a year-on-year rebound of 1.4% in 2024, indicating that January is part of a sustained recovery. The total financing amount for China's Medical Health Industry after 2022.
Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.
In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.
Express News | Innovent Receives Second Fast Track Designation From the U.S. FDA for Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
INNOVENT BIO IBI363 (a PD-1/IL-2α-bias bispecific antibody fusion protein) has again received the USA FDA fast track designation for the treatment of squamous non-small cell lung cancer.
San Francisco and Suzhou, China, February 17, 2025 /PR Newswire/ -- INNOVENT BIO (Hong Kong Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of Innovative Drugs for major diseases such as cancer, autoimmune diseases, metabolism, and ophthalmology, announced that its PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 has received fast track designation from the FDA in the USA, with the intended indication being anti-PD-.
